CytoDyn Inc. (CYDY)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Cyrus Arman M.B.A., Ph.D. | Senior Vice President of Business Operations | 451.17k | -- | 1982 |
| Dr. Jacob P. Lalezari M.D. | CEO & Member of Scientific Advisory Board | -- | -- | 1960 |
| Mr. Mitchell Cohen | Interim Chief Financial Officer | -- | -- | 1957 |
| Mr. Tyler Blok | Executive Vice President of Legal Affairs & Secretary | -- | -- | 1988 |
| Dr. Scott Hansen Ph.D. | Head of Research & Basic Science | -- | -- | -- |
| Mr. Joseph Meidling | Executive Director of Clinical Operations | -- | -- | -- |
| Ms. Cristina De Leon | Investors | -- | -- | -- |
CytoDyn Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 12
Description
CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Corporate Governance
Recent Events
- Apr 15, 202410-Q: Periodic Financial ReportsSee Full Filing
- Mar 28, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 15, 2024CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submissionSee Full Filing
- Feb 07, 2024S-1: Offering RegistrationsSee Full Filing
- Jan 16, 202410-Q: Periodic Financial ReportsSee Full Filing